lifestyle.ukuncut.org.uk

Author: IGC Pharma, Inc.

IGC Pharma Aligns Fiscal Year with Calendar Year to Enhance U.S. Investor Transparency and Comparability

January 9, 2026
IGC Pharma Aligns Fiscal Year with Calendar Year to Enhance U.S. Investor Transparency and Comparability

January 9, 2026
IGC Pharma Raises Capital to Advance IGC-AD1 Phase 2 Trial

January 8, 2026
IGC Pharma Announces Coverage Report by Ascendiant Capital Markets about the “Reports Q2 results. We believe more positive clinical data and progress in 2025/26 to be strong catalysts for stock. Raising P/T to $4.75.”

December 16, 2025
IGC Pharma Reports 65% Patient Enrollment Milestone in Phase 2 CALMA Alzheimer’s Agitation Trial

December 9, 2025